Zinc-finger nucleases (ZFNs), transcription activatorlike effector nucleases (TALENs), and CRISPR/Cas9 are the three prominent methods used in human-induced pluripotent stem cells (hiPSC) since genetic modifications can be efficiently localized at the generated DSB. Currently, ZFN is being phased out due to its high technical skill requirement and inefficiency. TALEN is more efficient than ZFN and requires~1800 bp for a target site, whereas CRISPR/Cas9 only requires 20 bp, increasing both screening targets and efficiency. However, TALEN has less restrictions in genetic site targeting as the presence of thymine at each 5′ end is sufficient compared to CRISPR/Cas9 which requires a protospacer adjacent motif (PAM) sequence. Additionally, due to the presence of the Fokl nuclease in TALEN, it produces fewer off-target effects compared to current CRISPR/Cas9-based tools. Studies have demonstrated that CRISPR/Cas9 could successfully knock out cell lines resulting in faster generation of iPSC cell lines with specific genes (Chen et al. 2015) while another study attempted to reprogram HEK293T cells into iPSC through activating human OCT4 promoter through dCas9-VP64 (Hu et al. 2014) . CRISPR/Cas9 can be utilized in gene correction in patient-specific iPSCs for muscular dystrophy and haemophilia to improve cell enrichment, drug screening, and differentiation protocols and simplify in vitro assays due to disease-specific single nucleotide mutations. Limitations such as non-existing biological readouts for the impact on cells and possible offtarget activities remain an issue; however, CRISPR/Cas9 has made progress in the safety of designer nucleases which is one of the main concerns regarding gene editing in iPSCs. CRISPR/Cas9 coupled with iPSC technology enables cell materials to be generated from patients which could be directly correlated with the clinical phenotype, though this remains a challenge as iPSC clones from a donor vary in differentiation capacity and cultural behaviour (Merkert and Martin 2016) .
CRISPR/Cas9 has a potential to be used as a gene drive to modify genes that are undesirable in species which transmit infectious diseases. For example, gene drives within mosquitoes could be targeted to block malaria transmission, an example being Anopheles stephensi which were adapted from mutagenic chain reaction (Gantz et al. 2015) . Infectious diseases spread by insects have decreased throughout the years, but mortality rates still remain high with 438,000 deaths caused by malaria alone in 2015 (WHO 2015) . Invasive species that negatively impact local ecosystems could also be regulated and controlled as many of the current solutions are either inefficient or have an adverse impact on natural species within an ecosystem; CRISPR/Cas9 would enable the specific targeting of certain species that are invasive without causing harm to other inhabitants. These possibilities are reduced and influenced by possible limitations such as the required presence of the PAM sequence and a time scale of generations to manifest. Short-spanned creature such as insects and rats would be achievable whereas long-lived animals could require an alternative solution. This also assumes that the trait will aid in organism survival; if it has a detrimental trait, there is the possibility that it would be phased out by natural selection.
Safety measurements should be considered, e.g. a Breversal drive^which could overwrite the initial gene drive and remove unwanted off effects (Esvelt et al. 2014) . Damage caused during the implementation of the Breversal drive^would be irreversible emphasizing the importance of a swift and rapid response period. We should question whether it would be effective in longer life-spanned species due to varying factors. There is an urgent need of evidence-based studies using an engineered endonuclease gene drive that could be successfully distributed within a wild population. Ethical issues on nonnatural involvement in nature's development should also be considered, before any clinical application be taken. CRISPR/Cas9 is a promising method to combat infectious diseases spread through insects, although challenges on its limitations and effectiveness still remain.
Cas9 results in irreversible effects and a higher possibility for off-target effects compared to dCas9 which decreases undesired and reversible effects to off-targets in regard to two distinct sgRNA sequences. Off-target effects and incomplete knockdowns of RNA interference (RNAi) methods on genome wide screens have been a prevalent issue. CRISPRi achieved a high knockdown rate with few off-target effects, and although off-targets were similar to TALE and other RNAi methods, it has potential to be further optimized (Gilbert et al. 2013 ). The oligonucleotide synthesis makes sgRNAs in Cas9 easier to be designed and cloned to achieve genome-wide screens. The function of dCas9-KRAB/sgRNA could modulate gene expression and generate higher sensitivity than shRNA to identify resistance-associated genes to ricin toxin in human cells (Gilbert et al. 2014) . CRISPR/dCas9 could also be modified to screen for function gains and to increase the scope of RNAi regulation in cells. Transcription repression will vary between genes in mammalian cells, and the binding of dCas9-sgRNA complex could be hindered by endogenous chromatin.
A transcriptional start site (TSS) was annotated using FANTOM5/GAGE promoter atlas and demonstrated that CRISPRi efficiency increased once the correct TSS was identified (Radzisheuskaya et al. 2016) . Preferences of sgRNA were considered and emphasized on chromatin accessibility of the target site, providing a possible guideline for a more efficient CRISPRi assay design. Metabolic engineering techniques based on dCas9 have been applied to unicellular organisms, with a potential for application in a complex multicellular organism. It would be exciting to implement dCas9 in biosensing and bioremediation through metabolic networks, resulting in desired traits to cells such as stress resistance. The applications of dCas9 may be extended to image genomic loci in cells, identify crucial proteins involved in pluripotency or differentiation, or control bacterial population through bacterial conjugation.
We should explore more potentials of Cas9 in clinical therapies. Cas9 can change the sensitivity and responses of cells to discovered drug, evidenced by the finding that CRISPR/Cas RGNs could alter the resistance of multidrugs in the model of a Galleria mellonella infection (Citorik et al. 2014) . The preliminary findings from Church and his colleagues showed that Cas9 could inactivate 62 porcine endogenous retroviruses (PERVs) in pig embryos (Nature News 2016). Such discovery could result in the first suitable non-human organ donor and have a significant impact in tissue engineering and regenerative medicine, as exampled to exhibit benefit from CRISPR/Cas9. In addition, the use of CRISPR as a screen for cancer genes has already been employed to identify and confirm potential genes with therapeutic potential. CRISPR can be used to edit selected targeted genes and generate mutation-specific or dominant cancerous cell lines to narrow down targeted genes and pathways in oncogenesis. CRISPR also has great potential for screening of drug efficacy and toxicity. For example, CRISPR-edited cancer cells with a specific gene mutation can be applied to define the sensitivity, response, and resistance of CRISPR-edited cells to the drug. The alterations of CRISPR-edited cell function by drug will confirm selected targets of potential treatments prior to or during clinical application. This will be a new future for clinical validation and screening of drugs and a new potential for clinical application of CRISPR to measure possible effects and toxicity profiles of drugs to mutation-specific cells.
CRISPR/Cas9 has a great future as an efficient method in gene engineering, although a number of drawbacks and limitations have to be overcome. CRISPR/Cas9-modified expression and function of epidermal growth factors or targeting V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) or histone deacetylase can be also considered for therapy in oncology and inheritable diseases. One of the most important issues is to address ethical dilemmas prior to implementation. With the discovery and development of gene therapy products, CRISPR/Cas9-based tools become more and more critical and necessary in clinical applications. We should carefully examine known and unknown limitations and how CRISPR can be further optimized and address ethical concerns in its application. Effective communication between the scientific community, industries, authorities, and public will become a necessity to determine the best use. It is crucial to remember the importance of transparency for the public throughout the process of discovery, development, and application of the technology.
